Status In progress
Process STA 2018
ID number 1478

Provisional Schedule

Committee meeting: 2 30 May 2019
Expected publication 21 August 2019

Project Team

Project lead Jeremy Powell

Email enquiries

Evidence Review Group / Assessment Group Warwick Evidence


Companies sponsors AstraZeneca (dapagliflozin)
Others Department of Health and Social Care
  NHS England
  Welsh Government
Patient carer groups JDRF
Professional groups Association of British Clinical Diabetologists
  Royal College of Pathologists
  Royal College of Physicians
  UK Clinical Pharmacy Association


Associated public health groups Public Health England
  Public Health Wales
Comparator companies Eli Lilly (insulin)
  Novo Nordisk (insulin)
  Sanofi (insulin)
  Wockhardt UK (insulin) (not participating)
General commentators All Wales Therapeutics and Toxicology Centre
  British National Formulary
  Department of Health, Social Services and Public Safety for Northern Ireland
  Healthcare Improvement Scotland
  Scottish Medicines Consortium
  Welsh Health Specialised Services Committee


Key events during the development of the guidance:

Date Update
25 April 2019 - 17 May 2019 Appraisal consultation
26 March 2019 Committee meeting: 1
10 August 2018 Invitation to participate
13 February 2018 In progress, Topic referred

For further information on how we develop guidance, please see our page about NICE technology appraisal guidance